PMC:7031805 / 15736-16718 JSONTXT

{"project":"TEST0","denotations":[{"id":"31965829-232-238-35","span":{"begin":519,"end":521},"obj":"[\"27839871\", \"28095420\", \"31504254\", \"31429998\", \"28377535\"]"},{"id":"31965829-229-235-36","span":{"begin":774,"end":776},"obj":"[\"28095420\"]"},{"id":"31965829-232-238-37","span":{"begin":777,"end":779},"obj":"[\"24002024\"]"},{"id":"31965829-235-241-38","span":{"begin":780,"end":782},"obj":"[\"29915537\"]"}],"text":"One opportunity that the accessibility of multiple new genetic models of human variants associated with epilepsy offers is evaluation of repurposed drugs. This requires a comprehensive functional evaluation of the effects of rare variants in vitro, which for ion channels is accessible. Functional evaluation of drug sensitivity of variant proteins will inform potential use of therapeutics, as will knowledge of the nature of the net functional effects as either gain of function or loss of function, or indeterminant.45-49 Genetic models—from cellular models to zebrafish and mouse models—harboring variants can then be screened for actions of Food and Drug Administration (FDA)-approved medications for efficacy in reducing electroencephalogram abnormalities and seizures46,50,51 as a step toward using pharmacological treatments. If the models capture patient-relevant features of epileptogenesis, early treatment within a vulnerable window might have long-lasting consequences."}

{"project":"MyTest","denotations":[{"id":"31965829-27839871-28638395","span":{"begin":519,"end":521},"obj":"27839871"},{"id":"31965829-28095420-28638395","span":{"begin":519,"end":521},"obj":"28095420"},{"id":"31965829-31504254-28638395","span":{"begin":519,"end":521},"obj":"31504254"},{"id":"31965829-31429998-28638395","span":{"begin":519,"end":521},"obj":"31429998"},{"id":"31965829-28377535-28638395","span":{"begin":519,"end":521},"obj":"28377535"},{"id":"31965829-28095420-28638396","span":{"begin":774,"end":776},"obj":"28095420"},{"id":"31965829-24002024-28638397","span":{"begin":777,"end":779},"obj":"24002024"},{"id":"31965829-29915537-28638398","span":{"begin":780,"end":783},"obj":"29915537"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"One opportunity that the accessibility of multiple new genetic models of human variants associated with epilepsy offers is evaluation of repurposed drugs. This requires a comprehensive functional evaluation of the effects of rare variants in vitro, which for ion channels is accessible. Functional evaluation of drug sensitivity of variant proteins will inform potential use of therapeutics, as will knowledge of the nature of the net functional effects as either gain of function or loss of function, or indeterminant.45-49 Genetic models—from cellular models to zebrafish and mouse models—harboring variants can then be screened for actions of Food and Drug Administration (FDA)-approved medications for efficacy in reducing electroencephalogram abnormalities and seizures46,50,51 as a step toward using pharmacological treatments. If the models capture patient-relevant features of epileptogenesis, early treatment within a vulnerable window might have long-lasting consequences."}

{"project":"2_test","denotations":[{"id":"31965829-27839871-28638395","span":{"begin":519,"end":521},"obj":"27839871"},{"id":"31965829-28095420-28638395","span":{"begin":519,"end":521},"obj":"28095420"},{"id":"31965829-31504254-28638395","span":{"begin":519,"end":521},"obj":"31504254"},{"id":"31965829-31429998-28638395","span":{"begin":519,"end":521},"obj":"31429998"},{"id":"31965829-28377535-28638395","span":{"begin":519,"end":521},"obj":"28377535"},{"id":"31965829-28095420-28638396","span":{"begin":774,"end":776},"obj":"28095420"},{"id":"31965829-24002024-28638397","span":{"begin":777,"end":779},"obj":"24002024"},{"id":"31965829-29915537-28638398","span":{"begin":780,"end":782},"obj":"29915537"}],"text":"One opportunity that the accessibility of multiple new genetic models of human variants associated with epilepsy offers is evaluation of repurposed drugs. This requires a comprehensive functional evaluation of the effects of rare variants in vitro, which for ion channels is accessible. Functional evaluation of drug sensitivity of variant proteins will inform potential use of therapeutics, as will knowledge of the nature of the net functional effects as either gain of function or loss of function, or indeterminant.45-49 Genetic models—from cellular models to zebrafish and mouse models—harboring variants can then be screened for actions of Food and Drug Administration (FDA)-approved medications for efficacy in reducing electroencephalogram abnormalities and seizures46,50,51 as a step toward using pharmacological treatments. If the models capture patient-relevant features of epileptogenesis, early treatment within a vulnerable window might have long-lasting consequences."}